Neuprozyme Therapeutics ApS: Financial statements 2025
CVR: 40010106
Source: annual report 2025, Danish Business Authority
01/07/2024 – 30/06/2025
Neuprozyme Therapeutics ApS (CVR 40010106) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -27,482 and a net result of DKK -25,574 compared with DKK -24,871 the year before. Equity in the 2025 report amounted to DKK 82,360. The solvency ratio was 75.5%.
- Gross Profit
- DKK -27,482
- Profit/Loss
- DKK -25,574
- Equity
- DKK 82,360
- Total Assets
- DKK 109,086
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -27K | -26K | 82K | 0 |
| 2024 | - | -27K | -25K | 108K | - |
| 2023 | - | -1K | -21K | 133K | - |
| 2022 | - | 576K | 436K | 154K | - |
| 2021 | - | 1M | -289K | -282K | - |
Official annual report
How creditworthy is Neuprozyme Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreAbout Neuprozyme Therapeutics ApS
Neuprozyme Therapeutics ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2018. The company is registered under the industry Fremstilling af andre organiske basiskemikalier. The management consists of John Pedersen. The board consists of John Pedersen and Lone Ballegaard Pedersen. The company is owned by LJP HOLDING ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -27,482 and a net result of DKK -25,574 compared with DKK -24,871 the year before. Equity in the 2025 report amounted to DKK 82,360.